Table 2 Actual management practices of DDIs in the NMV-r group according to the recommended DDI management
Actual DDI management practices according to the recommended DDI management | n (%) |
|---|---|
Total | 126 |
(a) Patients with reduced renal function (eGFR < 30 mL/min/1.73m2) | 0 |
(b) Patients with insufficient details on concomitant medications | 0 |
(c) Patients with concomitant medications categorized as “consider alternative COVID-19 therapy other than NMV-r” | 7 |
Temporary withhold/reduction/alteration of concomitant medications | 6 (85.7%) |
Details of management were unknown | 1 (14.3%) |
(d) Patients with concomitant medications categorized as “temporary withhold/reduction/alteration of concomitant medication” | 44 |
Temporary withhold/reduction/alteration of concomitant medications | 42 (95.5) |
Continuation of concomitant medication (monitoring the effects/adverse effects of each medication) | 2 (4.5) |
(e) Patients with concomitant medications categorized as “continuation of concomitant medication (monitoring the effects/adverse effects of each medication)” | 4 |
Temporary withhold/reduction/alteration of concomitant medications | 3 (75.0) |
Continuation of concomitant medication (monitoring the effects/adverse effects of each medication) | 1 (25.0) |
(f) Patients without concomitant medications requiring DDI management | 71 |
Temporary withhold/reduction/alteration of concomitant medications | 3 (4.2) |
No management for DDIs | 68 (95.8) |